Post-Cycle Health Assessment

What post-cycle testing can show

Post-cycle labs are read against baseline tests taken before starting and any on-cycle results. No label or trial sets a post-cycle schedule for research peptides, so the timings below come from related trials and user reports. A clinician orders and interprets these labs; the blood work schedule overview has the background.

Post-Cycle Testing Timeline

Immediate Post-Cycle (1-2 weeks)

Test	Purpose	Expected Finding
IGF-1	Clearing verification	Declining; slower after long-acting compounds
Glucose	Metabolic recovery	Direction of change only
Symptom assessment	Side effect resolution	Fluid-related effects fade (tesamorelin label)

Recovery Assessment (4-6 weeks)

Test	Purpose	Target
IGF-1	Return to baseline	Within the person's pre-cycle range
Fasting glucose	Insulin sensitivity	<100 mg/dL (ADA normal)
HbA1c	Glucose average	Still partly reflects the cycle

Extended Recovery (3 months)

Test	Purpose	Significance
HbA1c	Glucose average after the cycle	<5.7% (ADA normal)
Comparison to baseline	Change assessment	Similar to pre-cycle

System-Specific Recovery

Metabolic System

HbA1c reflects average blood glucose over the past two to three months, according to the American Diabetes Association, so a result drawn a month after stopping still includes weeks on the compound. Fasting glucose responds faster, but we found no trial that timed its return after a growth hormone secretagogue.

Marker	Recovery Timeline	Reference
Fasting glucose	Not studied	<100 mg/dL
HbA1c	2-3 months	<5.7%

GH/IGF-1 Axis

How fast IGF-1 settles depends on how long the compound acts. In a 2006 trial in healthy adults, one injection of CJC-1295, a long-acting GHRH analogue with an estimated half-life of 5.8-8.1 days, kept IGF-1 raised for 9-11 days; after multiple doses, mean IGF-1 stayed above baseline for up to 28 days. We found no published washout data for shorter-acting compounds such as ipamorelin or MK-677.

Body composition changes fade too. In a tesamorelin extension trial in people with HIV, visceral fat reaccumulated in those switched to placebo after 26 weeks.

Interpreting Post-Cycle Results

Successful Recovery

Finding	Interpretation
All markers back near baseline	No lasting change on these tests

Incomplete Recovery

Finding	Concern	Action
Persistent IGF-1 elevation	Long-acting compound, recent dose, or another cause	Clinician review
Elevated glucose	Insulin sensitivity, or HbA1c lag	ADA: diagnosis needs a repeat test
Hormonal changes	System adjustment	Medical consultation

Time Off Between Cycles

In community threads, breaks of 4-8 weeks are often described, sometimes with a rule of waiting until IGF-1 and glucose are back near baseline. These are community conventions, not tested protocols. No study has compared repeated cycles with breaks against continuous use or no use, and a normal post-cycle panel says nothing about repeated exposure over years.

What we still don't know

No study has measured how long IGF-1 or glucose markers take to settle after stopping an unapproved research peptide; the washout data above come from small or specific trial groups. A lab result also can't show what was in a gray-market vial, so an unchanged panel may say as much about the product as about recovery.